Pembrolizumab (Keytruda)
نویسندگان
چکیده
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well patient clinician perspectives, a drug or class. The inform non-binding recommendations that help guide decisions Canada's federal, provincial, territorial governments, with exception Quebec. This review assesses pembrolizumab (Keytruda), supplied as: powder for solution infusion: 50 mg lyophilized in single-use vial, reconstitution 100 mg/4 mL (25 mg/mL) vial administered an IV infusion over 30 minutes. Indication: Adjuvant treatment adult patients renal cell carcinoma (RCC) at intermediate-high high risk recurrence following nephrectomy, nephrectomy resection metastatic lesions.
منابع مشابه
Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma.
متن کامل
Pembrolizumab
The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and its approval in 2011 for the treatment of metastatic melanoma has heralded a new era in immuno-oncology. Subsequently, novel agents against the programmed death receptor 1 (PD-1)/programmed death receptor ligand 1 (PD-L1) axis have shown significant activity in melanoma and a variety of other tumor types...
متن کاملPembrolizumab reactivates pulmonary granulomatosis
Sarcoid like reaction is a well-known entity that occurs as a consequence to several malignancies or their therapies. Immunotherapy has gained a lot of interest in the past few years and has recently gained approval as first line therapy in multiple advanced stage malignancies. Pneumonitis has been described as complication of such therapy. Granulomatous inflammation has been only rarely report...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian journal of health technologies
سال: 2023
ISSN: ['2563-6596']
DOI: https://doi.org/10.51731/cjht.2023.541